ResMed Financial Statements (RMD)
|
|
|
|
Report date
|
|
|
30.06.2023 |
11.08.2023 |
30.06.2024 |
09.08.2024 |
08.08.2025 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
4 223 |
4 223 |
4 685 |
4 685 |
5 146 |
|
5 538 |
|
Operating Income, bln rub |
|
|
1 132 |
1 132 |
1 398 |
1 320 |
1 685 |
|
1 898 |
|
EBITDA, bln rub |
? |
|
1 340 |
1 359 |
1 693 |
1 534 |
1 913 |
|
2 102 |
|
Net profit, bln rub |
? |
|
897.6 |
897.6 |
1 021 |
1 021 |
1 401 |
|
1 520 |
|
|
OCF, bln rub |
? |
|
693.3 |
693.3 |
1 401 |
1 401 |
1 752 |
|
1 890 |
|
CAPEX, bln rub |
? |
|
134.0 |
134.0 |
114.9 |
114.9 |
89.9 |
|
135.7 |
|
FCF, bln rub |
? |
|
559.3 |
559.3 |
1 286 |
1 286 |
1 662 |
|
1 754 |
|
Dividend payout, bln rub
|
|
|
258.3 |
258.3 |
282.3 |
282.3 |
310.9 |
|
340.2 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
28.8% |
28.8% |
27.7% |
27.7% |
22.2% |
|
22.4% |
|
|
OPEX, bln rub |
|
|
1 204 |
1 224 |
1 225 |
1 335 |
1 370 |
|
1 518 |
|
Cost of production, bln rub |
|
|
1 867 |
1 867 |
2 063 |
2 030 |
2 091 |
|
2 121 |
|
R&D, bln rub |
|
|
287.6 |
287.6 |
307.5 |
307.5 |
331.3 |
|
359.0 |
|
Interest expenses, bln rub |
|
|
47.4 |
47.4 |
45.7 |
45.7 |
12.6 |
|
29.0 |
|
|
Assets, bln rub |
|
|
6 752 |
6 752 |
6 872 |
6 872 |
8 174 |
|
8 784 |
|
Net Assets, bln rub |
? |
|
4 130 |
4 130 |
4 864 |
4 864 |
5 968 |
|
6 492 |
|
Debt, bln rub |
|
|
1 580 |
1 580 |
873.9 |
873.9 |
851.8 |
|
843.2 |
|
Cash, bln rub |
|
|
227.9 |
227.9 |
238.4 |
238.4 |
1 209 |
|
1 661 |
|
Net debt, bln rub |
|
|
1 352 |
1 352 |
635.6 |
635.6 |
-357.6 |
|
-817.3 |
|
|
Ordinary share price, rub |
|
|
218.5 |
218.5 |
191.4 |
191.4 |
258.0 |
|
207.0 |
|
Number of ordinary shares, mln |
|
|
0.000 |
146.8 |
147.0 |
147.0 |
146.7 |
|
146.5 |
|
|
Market cap, bln rub |
|
|
0 |
32 068 |
28 143 |
28 143 |
37 853 |
|
30 314 |
|
EV, bln rub |
? |
|
1 352 |
33 420 |
28 778 |
28 778 |
37 495 |
|
29 497 |
|
Book value, bln rub |
|
|
4 130 |
807 |
4 864 |
1 536 |
2 456 |
|
3 024 |
|
|
EPS, rub |
? |
|
|
6.12 |
6.94 |
6.94 |
9.55 |
|
10.4 |
|
FCF/share, rub |
|
|
|
3.81 |
8.75 |
8.75 |
11.3 |
|
12.0 |
|
BV/share, rub |
|
|
|
5.50 |
33.1 |
10.4 |
16.7 |
|
20.6 |
|
|
EBITDA margin, % |
? |
|
31.7% |
32.2% |
36.1% |
32.7% |
37.2% |
|
38.0% |
|
Net margin, % |
? |
|
21.3% |
21.3% |
21.8% |
21.8% |
27.2% |
|
27.4% |
|
FCF yield, % |
? |
|
0.00% |
1.74% |
4.57% |
4.57% |
4.39% |
|
5.79% |
|
ROE, % |
? |
|
21.7% |
21.7% |
21.0% |
21.0% |
23.5% |
|
23.4% |
|
ROA, % |
? |
|
13.3% |
13.3% |
14.9% |
14.9% |
17.1% |
|
17.3% |
|
|
P/E |
? |
|
0.00 |
35.7 |
27.6 |
27.6 |
27.0 |
|
19.9 |
|
P/FCF |
|
|
0.00 |
57.3 |
21.9 |
21.9 |
22.8 |
|
17.3 |
|
P/S |
? |
|
0.00 |
7.59 |
6.01 |
6.01 |
7.36 |
|
5.47 |
|
P/BV |
? |
|
0.00 |
39.7 |
5.79 |
18.3 |
15.4 |
|
10.0 |
|
EV/EBITDA |
? |
|
1.01 |
24.6 |
17.0 |
18.8 |
19.6 |
|
14.0 |
|
Debt/EBITDA |
|
|
1.01 |
1.00 |
0.38 |
0.41 |
-0.19 |
|
-0.39 |
|
|
R&D/CAPEX, % |
|
|
214.7% |
214.7% |
267.7% |
267.7% |
368.6% |
|
264.5% |
|
|
CAPEX/Revenue, % |
|
|
3.17% |
3.17% |
2.45% |
2.45% |
1.75% |
|
2.45% |
|
| ResMed shareholders |
